[Efficacy and costs of XXXX therapy in Poland--regional approach].

@entity43 @entity1 @entity5 @entity283
@entity43 ( @entity43 ) affects over 3 000 @entity1 in Poland annually The efficacy of the therapy remains relatively low due to challenges of systematic improvement in the early detection @entity43 rates. International comparisons indicate a positive correlation between health expenditures and 5-year survival rates of @entity5 @entity1 . To the best of our knowledge, our study has been the first to present a correlation between the 5-year survival rates (SRs) and the cost of @entity43 therapy in particular regions of Poland. MATERIAL AND METHODS: The study was based on the National Health Fund (NHF) data, available in the Disease Treatment Registry The analysis included approximately 13,000 @entity43 @entity1 who started their treatment between 2005 and 2008 to allow for the evaluation of long-term therapy results. The 5-year survival rates were analyzed in relation to average @entity283 in various regions of Poland, distinguishing the population of @entity1 aged 45-64 years. RESULTS: The 5-year survival rate in the cohorts diagnosed in 2005 and 2008 changed marginally from 42% to 43%, maintaining relatively large differences between the regions (from 35% to 53% in @entity1 diagnosed in 2008). The @entity283 in particular regions differed significantly: mean cost for the entire treatment cycle ranged from 31.600 PLN do 58.000 PLNperperson among @entity1 diagnosed in 2008. No significant correlation between the survival and the cost was found. CONCLUSIONS: SRs of @entity43 @entity1 in particular regions of Poland are not correlated with average treatment cost. Thus, the differences in SRs between various regions of Poland have their source in other factors, e.g., clinical stage at diagnosis, or prevailing treatment patterns in the given region. Further studies may decrease regional discrepancies in @entity1 care and SRs in @entity43 subjects.
